Items where Author is "Siccardi, Marco"

Up a level
Export as [feed] RSS
Group by: Item Type | No Grouping
Number of items: 6.

Giardiello, Marco, Liptrott, Neill, McDonald, Tom, Moss, Darren, Siccardi, Marco, Martin, Phil, Smith, Darren, Gurjar, Rohan, Rannard, Steven and Owen, Andrew (2016) Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. Nature Communications, 7. p. 13184. ISSN 2041-1723

Siccardi, Marco, Martin, Phillip, Smith, Darren, Curley, Paul, McDonald, Tom, Giardiello, Marco, Liptrott, Neill, Rannard, Steven and Owen, Andrew (2016) Towards a rational design of solid drug nanoparticles with optimised pharmacological properties. Journal of Interdisciplinary Nanomedicine, 1 (3). pp. 110-123. ISSN 2058-3273

Martin, Philip, Giardiello, Marco, McDonald, Tom, Smith, Darren, Siccardi, Marco, Rannard, Steven and Owen, Andrew (2015) Augmented inhibition of CYP3A4 in human primary hepatocytes by ritonavir solid drug nanoparticles. Molecular Pharmaceutics, 12 (10). pp. 3556-3568. ISSN 1543-8384

McDonald, Tom, Giardiello, Marco, Martin, Philip, Siccardi, Marco, Liptrott, Neill, Smith, Darren, Roberts, Phill, Curley, Paul, Schipani, Alessandro, Khoo, Saye, Long, James, Foster, Alison, Rannard, Steven and Owen, Andrew (2014) Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro-In Vivo Correlation. Advanced Healthcare Materials, 3 (3). pp. 400-411. ISSN 21922640

Martin, Philip, Liptrott, Neill, McDonald, Tom, Giardiello, Marco, Roberts, Phill, Curley, Paul, Smith, Darren, Siccardi, Marco, Rannard, Steven and Owen, Andrew (2013) Enhanced pharmacological properties of efavirenz formulated as solid drug nanoparticles. In: 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), 3 - 6 March 2013, Atlanta, USA.

Moss, Darren, Kwan, Wai San, Liptrott, Neill, Smith, Darren, Siccardi, Marco, Khoo, Saye, Back, David and Owen, Andrew (2011) Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir. Antimicrobial Agents and Chemotherapy, 55 (2). pp. 879-887. ISSN 0066-4804

This list was generated on Wed Nov 30 21:14:16 2022 UTC.